L-アルギニンは,長期喫煙者の冠動脈血管運動を正常化する
R Campisi1, J Czernin, H Schöder
1Department of Molecular and Medical Pharmacology, UCLA School of Medicine, and Laboratory of Structural Biology and Molecular Medicine, University of California, Los Angeles, 90095-1735, USA.
Circulation
|February 2, 1999
まとめ
長期喫煙者は異常な冠動脈血管運動反応を示しますが,L-アルギニンを補充すると,この機能不全が逆転し,内皮の関与が示唆されます. この研究は,PETイメージングを強調しています.
科学分野:
- 心血管生理学 心血管の生理学
- 内皮機能の研究
- 核心臓病の心臓病学について
背景:
- PETを用いた非侵襲性心筋血流 (MBF) 測定は,健康な長期喫煙者における冷圧テストに対する冠動脈血管運動反応の低下を明らかにした.
- 潜在的原因である冠動脈内皮機能不全は,酸化窒素合成酵素の基質であるL-アルギニンによって逆転させられると仮定した.
研究 の 目的:
- 喫煙者において観察される異常な血管運動反応における冠動脈内皮機能不全の役割を調査する.
- L-アルギニンサプリメントが喫煙者における冷圧圧力のテストに反応して正常な血管運動機能を回復できるかどうかを判断する.
主な方法:
- 13Nラベル付アンモニアとPETを用いた定量化MBFは,健康な喫煙者11人と,年齢に匹敵する非喫煙者12人に実施した.
- 静脈内投与L-アルギニンを投与し,休憩とストレスのときのMBF応答を評価するために,別の日に冷圧器テストを実施しました.
主要な成果:
- 喫煙者は,非喫煙者と比較して,冷たい圧力のテスト中にMBFの鈍化した増加を示しました (11%対44%の増加).
- L-アルギニンの投与後,冷圧器テストに対するMBF反応は,喫煙者と非喫煙者の間で類似した (両方のグループで48%の増加).
- L-アルギニンは,どちらのグループでも休息中のMBFに影響を与えませんでした.
結論:
- 発見は,冠動脈内皮を長期喫煙者における異常な血管運動反応の主な部位として示唆しています.
- コールドプレッサー検査とPET画像の組み合わせは,ヒトにおける冠動脈内皮機能不全を特定するための非侵襲的方法として役立つ可能性があります.
関連する概念動画
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...